EnWave Successfully Commercializes nutraREV(TM) Food Dehydration ...(d-looking information based on managemen...)

Date:3/2/2009

d-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. The forward-looking statement in this press release includes: "EnWave expects", "plans to develop", and "is designed to". These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's nutraREV(TM) technology can or will improve processes in the food industry; even if the Company's nutraREV(TM) technology can be used as described in this document, there is no guarantee that such use will result in future orders for the Company's nutraREV(TM) technology.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.

'/>"/>

SOURCE EnWave Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. EpiStem Successfully Complete First Year of Mucositis Tests for NIH Biodefence Programme
2. Life on Mars pregnancy test successfully launched
3. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
4. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
5. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
6. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
7. TopoTarget Successfully Buys Back Full Control of Belinostat
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
10. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
11. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications